All In Biotech

Drug Trial Radar · NCT07547995

A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.

A Phase II Clinical Study to Assess the Efficacy and Safety of GenSci048 in Subjects With Active Non-infectious Uveitis.

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

74

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Dec 14, 2027

Study completion Jan 13, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.

Conditions

  • Uveitis

Interventions

  • GenSci048Drug

    Administered SC.

  • PlaceboDrug

    Administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The effectiveness of GenSci048 administered by subcutaneous injectionTime frame: 25 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye & Ent Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.